Kasprzyk Mariusz, Sławiński Grzegorz, Musik Martyna, Marciniak Łukasz, Dyszkiewicz Wojciech, Piwkowski Cezary, Gałęcki Bartłomiej
Department of Thoracic Surgery, Poznan University of Medical Sciences, Poznan, Poland.
Kardiochir Torakochirurgia Pol. 2015 Mar;12(1):18-25. doi: 10.5114/kitp.2015.50563. Epub 2015 Mar 31.
The selection of treatment for local recurrence in patients with non-small-cell lung cancer (NSCLC) depends on the possibility of performing a radical tumor resection, the patient's performance status, and cardiopulmonary efficiency. Compared with chemoradiotherapy, surgical treatment offers a greater chance of long-term survival, but results in completion pneumonectomy and is associated with a relatively high rate of complications.
Aim of the study was to evaluate early and long-term results of surgery and conservative treatment (chemoradiotherapy) in patients with local NSCLC recurrence.
Between 1998 and 2011, 1697 NSCLC patients underwent lobectomy or bilobectomy at the Department of Thoracic Surgery in Poznań. Among them, 137 patients (8.1%) were diagnosed with cancer recurrence; chemotherapy or chemoradiotherapy was provided to 116 patients; 21 patients (15.3%) were treated with completion pneumonectomy. The median time from primary surgery to recurrence was 13.4 months. No metastases to N2 lymph nodes were observed among the patients undergoing surgery; in 7 patients N1 lymph node metastases were confirmed.
The rate of complications after surgery was significantly higher in comparison with conservative therapy (80.9% vs. 48.3%). Patients treated with surgery were most likely to suffer from complications associated with the circulatory system (80.9%), while hematologic complications were dominant in the group undergoing oncological treatment (41.4%). There were no perioperative deaths after completion pneumonectomy. The age of the patients was the only factor which significantly influenced the incidence of complications in both groups of patients. Analysis of the survival curves demonstrated statistically significant differences in survival between the groups treated with surgery, chemoradiotherapy, and chemotherapy (p = 0.00001). Five-year survival probability was significantly higher among patients treated surgically as compared to patients undergoing systemic therapy.
Despite the significant rate of postoperative complications (mostly circulatory), the long-term results of the surgical treatment of local NSCLC recurrence are more favorable than those achieved with chemoradiotherapy. The success of surgical treatment is conditioned on the exclusion of metastasis in N2 lymph nodes.
非小细胞肺癌(NSCLC)患者局部复发的治疗选择取决于能否进行根治性肿瘤切除、患者的身体状况以及心肺功能。与放化疗相比,手术治疗提供了更大的长期生存机会,但会导致全肺切除,且并发症发生率相对较高。
本研究的目的是评估局部NSCLC复发患者手术和保守治疗(放化疗)的早期和长期结果。
1998年至2011年间,1697例NSCLC患者在波兹南胸外科接受了肺叶切除术或双肺叶切除术。其中,137例患者(8.1%)被诊断为癌症复发;116例患者接受了化疗或放化疗;21例患者(15.3%)接受了全肺切除术。从初次手术到复发的中位时间为13.4个月。接受手术的患者中未观察到N2淋巴结转移;7例患者确诊为N1淋巴结转移。
与保守治疗相比,手术后的并发症发生率显著更高(80.9%对48.3%)。接受手术治疗的患者最容易出现与循环系统相关的并发症(80.9%),而血液学并发症在接受肿瘤治疗的组中占主导地位(41.4%)。全肺切除术后无围手术期死亡。患者年龄是两组患者中唯一显著影响并发症发生率的因素。生存曲线分析表明,手术、放化疗和化疗治疗组之间的生存率存在统计学显著差异(p = 0.00001)。与接受全身治疗的患者相比,手术治疗患者的五年生存概率显著更高。
尽管术后并发症发生率较高(主要是循环系统并发症),但局部NSCLC复发手术治疗的长期结果比放化疗更有利。手术治疗的成功取决于排除N2淋巴结转移。